

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

Evaluation of the Efficacy of Ginger Supplementation with Pellet Formulation in Children with Juvenile Idiopathic Arthritis(JIA)

Protocol summary

Study aim

Evaluation of the efficacy of ginger supplementation on the severity of JIA according to the ACR-Pedi30 Score

Design

A placebo-controlled, randomized, double-blinded, phase 2-3 clinical trial on 50 patients with JIA. Block randomization was used for randomization.

Settings and conduct

The study will be conducted as a double-blind clinical trial in experimental and control groups. Fifty children (aged 6-16 years) referred to rheumatology clinic of Akbar hospital, who have been diagnosed with JIA according to the ACR guideline, will be included in the study. Then, they will be randomly assigned to experimental or control groups.

Participants/Inclusion and exclusion criteria

inclusion criteria: - Children (aged 6-16 years) referred to rheumatology clinic of Akbar hospital, who have been diagnosed with JIA according to the ACR guideline. - Obtaining informed consent of the patient / patient's parents
exclusion criteria: -A child with a history of underlying disease, including cardiac, renal, hepatic, biliary, gastrointestinal, or rheumatic disorders (other than JIA), at the time of enrollment -Use of anticoagulants (such as warfarin) or antiplatelet agents - Diabetic patients

Intervention groups

Intervention group: included patients will receive standard treatment of JIA and ginger pellets (containing hydro-alcoholic ginger extract equivalent to 250 mg of ginger rhizome powder, standardized based on Shogaol and phenolic acids contents) twice a day for 3 months.
Control group: Included patients will receive standard treatment of JIA and placebo pellets (twice daily) for 3 months.

Main outcome variables

Disease severity will be assessed at baseline, end of the first month, and end of the third month of treatment using the ACR-Pedi30 Score.

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20191221045837N4**

Registration date: **2021-12-08, 1400/09/17**

Registration timing: **prospective**

Last update: **2021-12-08, 1400/09/17**

Update count: **0**

Registration date

2021-12-08, 1400/09/17

Registrant information

Name

Zinat Heidari

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 51 3180 1584

Email address

heidarizn@mums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2022-01-05, 1400/10/15

Expected recruitment end date

2024-01-21, 1402/11/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of the Efficacy of Ginger Supplementation with Pellet Formulation in Children with Juvenile Idiopathic Arthritis(JIA)

Public title

Evaluation of the Efficacy of Ginger Supplementation with Pellet Formulation in Children with Juvenile Idiopathic Arthritis(JIA)

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Children (aged 6-16 years) referred to rheumatology clinic of Akbar hospital, who have been diagnosed with JIA according to the ACR Guideline. Obtaining informed consent of the patient / patient's parents

Exclusion criteria:

A child with a history of underlying disease, including cardiac, renal, hepatic, biliary, gastrointestinal, or rheumatic disorders (other than JIA), at the time of enrollment Use of anticoagulants (such as warfarin) or antiplatelet agents Diabetic patients

Age

From **6 years** old to **16 years** old

Gender

Both

Phase

N/A

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

Sample size

Target sample size: **50**

Randomization (investigator's opinion)

Randomized

Randomization description

Block randomization Randomization tool: <https://www.sealedenvelope.com/> How to make a random sequence: To perform this method, the number of intervention groups (two groups A and B), the volume of each block (4 in each block) and sample size (50 patients) were entered into the website. Then, the site creates a randomization list of 13 blocks, each contains 4 patients.

Blinding (investigator's opinion)

Double blinded

Blinding description

Patients, evaluators, data analysts, and technicians are blinded.

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Mashhad University of Medical Sciences

Street address

Central department of Mashhad University of Medical Sciences, next to Alton Tower, Daneshgah Street, Mashhad, Khorasan Razavi Province, Iran.

City

Mashhad

Province

Razavi Khorasan

Postal code

13944-91388

Approval date

2020-10-10, 1399/07/19

Ethics committee reference number

IR.MUMS.REC.1399.460

Health conditions studied

1

Description of health condition studied

juvenile idiopathic arthritis (JIA)

ICD-10 code

M08

ICD-10 code description

Juvenile arthritis

Primary outcomes

1

Description

Disease severity will be assessed at baseline, end of the first month, and end of the third month of treatment using the ACR-Pedi30 Score. The core criteria for ACR Pedi 30 score are: 1) physician global assessment of disease activity (PhGA); 2) parent/patient global assessment of overall well-being; 3) functional ability; 4) number of joints with active arthritis; 5) number of joints with limited range of motion; and 6) ESR.

Timepoint

At baseline, end of the first month, and end of the third month of treatment

Method of measurement

1) physician global assessment of disease activity (PhGA); 2) parent/patient global assessment of overall well-being; 3) functional ability; 4) number of joints with active arthritis; 5) number of joints with limited range of motion; and 6) ESR.

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: included patients will receive standard treatment of JIA and ginger pellets (containing hydro-alcoholic ginger extract equivalent to 250 mg of ginger rhizome powder, standardized based on Shogaol and phenolic acids contents) twice a day for 3 months.

Category

Treatment - Drugs

2

Description

Control group: Included patients will receive standard treatment of JIA and placebo pellets (twice daily) for 3 months.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Akbar pediatric hospital

Full name of responsible person

Zinat Heidari

Street address

Akbar pediatric hospital, Shahid Kaveh Boulevard, Mashhad, Khorasan Razavi.

City

Mashhad

Province

Razavi Khorasan

Postal code

9177897157

Phone

+98 51 3871 3801

Fax

+98 51 3870 9201

Email

ak.pr@mums.ac.ir

Web page address

<https://akbar.mums.ac.ir/>

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Mashhad University of Medical Sciences

Full name of responsible person

Mohsen Tafaghodi

Street address

Central department of Mashhad University of Medical Sciences, next to Alton Tower, Daneshgah Street, Mashhad, Khorasan Razavi Province, Iran.

City

Mashhad

Province

Razavi Khorasan

Postal code

9138813944

Phone

+98 51 3841 1538

Fax

+98 51 3843 0249

Email

vcresraech@mums.ac.ir

Web page address

<https://v-research.mums.ac.ir/>

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Mashhad University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Mashhad University of Medical Sciences

Full name of responsible person

Zinat Heidari

Position

Assistant Professor

Latest degree

Specialist

Other areas of specialty/work

Medical Pharmacy

Street address

Faculty of Pharmacy, University Campus, Azadi Square, Mashhad, Khorasan Razavi.

City

Mashhad

Province

Razavi Khorasan

Postal code

9177948954

Phone

+98 51 3180 1584

Fax

Email

heidarizn@mums.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Mashhad University of Medical Sciences

Full name of responsible person

Zinat Heidari

Position

Assistant Professor

Latest degree

Specialist

Other areas of specialty/work

Medical Pharmacy

Street address

Faculty of Pharmacy, University Campus, Azadi Square, Mashhad, Khorasan Razavi.

City

Mashhad

Province

Razavi Khorasan

Postal code

9177948954

Phone

+98 51 3180 1584

Fax**Email**

heidarizn@mums.ac.ir

Person responsible for updating data

Contact

Name of organization / entity

Mashhad University of Medical Sciences

Full name of responsible person

Zinat Heidari

Position

Assistant Professor

Latest degree

Specialist

Other areas of specialty/work

Medical Pharmacy

Street address

Faculty of Pharmacy, University Campus, Azadi Square, Mashhad, Khorasan Razavi.

City

Mashhad

Province

Razavi Khorasan

Postal code

9177948954

Phone

+98 51 3180 1584

Fax**Email**

heidarizn@mums.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

At the end of study, all medical records of patients will be shared.

When the data will become available and for how long

The access period starts 6 months after the publication.

To whom data/document is available

Researchers affiliated to academic, scientific and industrial institutes

Under which criteria data/document could be used

No one is allowed to use the documents except the principal researcher.

From where data/document is obtainable

Send an email to Dr. Zeinat Heydari.

heidarizn@mums.ac.ir

What processes are involved for a request to access data/document

Send an email to Dr. Zeinat Heydari.

heidarizn@mums.ac.ir

Comments